Hussain Borghaei, DO, MS, discusses the significance of the overall survival data update from the KEYNOTE-001 trial. This trial investigated the PD-1 inhibitor pembrolizumab as a treatment for patients with advanced non–small cell lung cancer.
Hussain Borghaei, DO, MS, chief of the Division of Thoracic Medical Oncology, professor in the Department of Hematology/Oncology, and co-director of the Immune Monitoring Facility at Fox Chase Cancer Center, discusses the significance of the overall survival (OS) data update from the KEYNOTE-001 trial. This trial investigated the PD-1 inhibitor pembrolizumab (Keytruda) as a treatment for patients with advanced nonsmall cell lung cancer (NSCLC).
According to thefindings presented at the 2019 ASCO Annual Meeting, 550 patients with advanced or metastatic NSCLC, who were either treatment-naïve or had received prior treatment, were enrolled and received pembrolizumab. These findings showed that 15.5% of patients with advanced NSCLC who had received prior therapy were alive at the 5-year mark; 23.2% of newly diagnosed patients were also alive at 5 years.
The survival rate has been limited for the majority of patients with advanced NSCLC who do not have molecularly driven tumors, Borghaei says. The survival rate seen in the KEYNOTE-001 appears promising for this patient population, which historically has been about 5%.